Physician profile
Effat Bennett
NPI 1457004335
$1,121.01
in general payments reported to CMS, 2019-2025
13 companies · $630 in 2025
The $630 reported for 2025 was more than what 78% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.76 · 2023: $74.55 · 2024: $374 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.25 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $346.88 | 2024-2025 | Datroway, Enhertu |
| Janssen Biotech, INC. | $180.21 | 2024-2025 | Rybrevant, Tecvayli, Talvey |
| Jazz Pharmaceuticals INC. | $111.71 | 2025 | |
| Exelixis INC. | $99.00 | 2024 | |
| Merck Sharp & Dohme LLC | $86.16 | 2022-2024 | Keytruda |
| Abbvie INC. | $64.56 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $45.56 | 2024 | Onivyde, Somatuline Depot |
| Incyte Corporation | $44.65 | 2025 | Zynyz, Monjuvi |
| Stemline Therapeutics INC. | $38.97 | 2024 | Orserdu |
| Genmab U.S., INC. | $32.01 | 2023 | Epkinly |
| Astrazeneca Pharmaceuticals Lp | $28.30 | 2024 | Calquence |
| Gilead Sciences, INC. | $24.60 | 2024 | |
| Sandoz INC. | $18.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Effat Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.